Aurora kinases as targets in drug-resistant neuroblastoma cells

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Michaelis, Martin ^a,b   Selt, Florian ^a,d   Rothweiler, Florian ^a   Löschmann, Nadine ^a   Nüsse, Benedikt ^a   Dirks, Wilhelm G ^c   Zehner, Richard ^a   Cinatl, Jindrich ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY OF KENT   (United Kingdom)

^c LEIBNIZ INSTITUTE DSMZ GERMAN COLLECTION OF MICROORGANISMS AND CELL CULTURES   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALISERTIB; AURORA A KINASE; AURORA B KINASE; AURORA KINASE; CISPLATIN; DOXORUBICIN; HISTONE H3; MULTIDRUG RESISTANCE PROTEIN 1; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; TOZASERTIB; VINCRISTINE; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; AURKA PROTEIN, HUMAN; AURKB PROTEIN, HUMAN; AZEPINE DERIVATIVE; HISTONE; IMIDAZOLE DERIVATIVE; MDM2 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SPECIFICITY; DRUG TARGETING; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PRIMARY CELL CULTURE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AURORA KINASE A; AURORA KINASE B; AZEPINES; BRAIN NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; IMIDAZOLES; NEUROBLASTOMA; P-GLYCOPROTEINS; PHOSPHORYLATION; PIPERAZINES; PRIMARY CELL CULTURE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MDM2; PYRIMIDINES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84907560588     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108758     Document Type: Article

References (48)

1. Glover DM, Leibowitz MH, McLean DA, Parry H (1995) Mutations in aurora prevent centrosome separation leading to the formation of monopolar spindles. Cell 81: 95-105.
2. Kollareddy M, Zheleva D, Dzubak P, Brahmkshatriya PS, Lepsik M, et al. (2012) Aurora kinase inhibitors: progress towards the clinic. Invest New Drugs 30: 2411-2432.
3. Morgenstern DA, Baruchel S, Irwin MS (2013) Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy. J Pediatr Hematol Oncol 35: 337-347.
4. Park JR, Bagatell R, London WB, Maris JM, Cohn SL, et al. (2013) Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatr Blood Cancer 60: 985-993.
5. Shang X, Burlingame SM, Okcu MF, Ge N, Russell HV, et al. (2009) Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol Cancer Ther 8: 2461-2469.
6. Inandiklioglu N, Yilmaz S, Demirhan O, Erdogan S, Tanyeli A (2012) Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma. Asian Pac J Cancer Prev 13: 5391-5397.
7. Morozova O, Vojvodic M, Grinshtein N, Hansford EM, Blakely KM, et al. (2010) System-level analysis of neuroblastoma tumor-initiating cells implicates AURKB as a novel drug target for neuroblastoma. Clin Cancer Res 16: 4572 -4582.
8. Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, et al. (2010) Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 55: 26-34.
9. Carol H, Boehm I, Reynolds CP, Kang MH, Maris JM, et al. (2011) Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol 68: 1291-1304.
10. Faisal A, Vaughan L, Bavetsias V, Sun C, Atrash B, et al. (2011) The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCNamplified neuroblastoma in vivo. Mol Cancer Ther 10: 2115-2123.
11. Brockmann M, Poon E, Berry T, Carstensen A, Deubzer HE, et al. (2013) Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell 24: 75-89.
12. Horwacik I, Durbas M, Boratyn E, Wçgrzyn P, Rokita H (2013) Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells. Cancer Lett 341: 248-264.
13. Museal JA, Scorsone KA, Zhang L, Ecsedy JA, Berg SL (2013) Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Invest New Drugs 31: 39-45.
14. Romain C, Paul P, Kim KW, Lee S, Qiao J, et al. (2014) Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. J Pediatr Surg 49: 159-165.
15. Romain CV, Paul P, Lee S, Qiao J, Chung DH (2014) Targeting Aurora Kinase A Inhibits Hypoxia-mediated Neuroblastoma Cell Tumorigenesis. Anticancer Res 34: 2269-2274.
16. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, et al. (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10: 262-267.
17. Qi W, Cooke LS, Liu X, Rimsza L, Roe DJ, et al. (2011) Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mande cell lymphoma. Biochem Pharmacol 81: 881-890.
18. Kotchetkov R, Cinati J, Blaheta R, Vogel JU, Karaskova J, et al. (2003) Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int J Cancer 104: 36-43.
19. Kotchetkov R, Driever PH, Cinati J, Michaelis M, Karaskova J, et al. (2005) Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. Int J Oncol 27: 1029-1037.
20. Michaelis M, Kleinschmidt MC, Barth S, Rothweiler F, Geiler J, et al. (2010) Anti-cancer effects of artesunate in a panel of chemoresistant neuroblastoma cell lines. Biochem Pharmacol 79: 130-136.
21. Michaelis M, Rothweiler F, Barth S, Cinati J, van Rikxoort M, et al. (2011) Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis 2: e243.
22. Löschmann N, Michaelis M, Rothweiler F, Zehner R, Cinati J, et al. (2013) Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs. Transi Oncol 6: 685-696.
23. Rothweiler F, Michaelis M, Brauer P, OtteJ, Weber K, et al. (2010) Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells. Neoplasia 12: 1023-1030.
24. Michaelis M, Rothweiler F, Nerreter T, Sharifi M, Ghafourian T, et al. (2014) Karaniin interferes with ABCBl, ABCCl, and ABCG2. J Pharm Pharm Sci 17: 92-105.
25. Weber K, Mock U, Petrowitz B, Bartsch U, Fehse B (2010) Lentiviral gene ontology (LeGO) vectors equipped with novel drug-selectable fluorescent proteins: new building blocks for cell marking and multi-gene analysis. Gene Ther 17: 511-520.
26. Weber K, Thomaschewski M, Benten D, Fehse B (2012) RGB marking with lentiviral vectors for multicolor clonal cell tracking. Nat Protoc 7: 839-849.
27. Michaelis M, Paulus C, Löschmann N, Dauth S, Stange E, et al. (2011) The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication. Cell Mol Life Sei 68: 1079-1090.
28. Guo J, Anderson MG, Tapang P, Palma JP, Rodriguez LE, et al. (2009) Identification of genes that confer tumor cell resistance to the aurora B kinase inhibitor, AZD1152. Pharmacogenomics J 9: 90-102.
29. Tavanti E, Sero V, Vella S, Fanelli M, Michelacci F, et al. (2013) Preclinical validation of Aurora kinases-targeting drugs in osteosarcoma. BrJ Cancer 109: 2607-2618.
30. Tao Y, Zhang P, Frascogna V, Lecluse Y, Auperin A, et al. (2007) Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells. BrJ Cancer 1664-1672.
31. Tao Y, Zhang P, Girdler F, Frascogna V, Castedo M, et al. (2008) Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152. Oncogene 27: 3244-3255.
32. Dar AA, Belkhiri A, Ecsedy J, Zaika A, El-Rifai W (2008) Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res 68: 8998-9004.
33. Kojima K, Konopleva M, Tsao T, Nakakuma H, Andreeff M (2008) Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. Blood 112: 2886-2895.
34. Donato NJ, Fang D, Sun H, Giannola D, Peterson LF, et al. (2010) Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia. Biochem Pharmacol 79: 688-697.
35. Görgün G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, et al. (2010) A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 115: 5202-5213.
36. Sehdev V, Peng D, Soutto M, Washington MK, Revetta F, et al. (2012) The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Mol Cancer Ther 11: 763-774.
37. Sehdev V, Katsha A, Ecsedy J, Zaika A, Belkhiri A, et al. (2013) The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas. Cancer 119: 904-914.
38. Kalous O, Conklin D, Desai AJ, Dering J, Goldstein J, et al. (2013) AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53. Breast Cancer Res Treat 141: 397-108.
39. Cheok CF, Kua N, Kaldis P, Lane DP (2010) Combination of nutlin-3 and VX680 selectively targets p53 mutant cells with reversible effects on cells expressing wild-type p53. Cell Death Differ 17: 1486-1500.
40. Ikezoe T, Yang J, Nishioka C, Yokoyama A (2010) p53 is critical for the Aurora B kinase inhibitor-mediated apoptosis in acute myelogenous leukemia cells. IntJ Hematol 91: 69-77.
41. Cinatl J Jr, Speidel D, Hardcastle I, Michaelis M, (in press) Resistance acquisition to MDM2 inhibitors. Biochem Soc Trans in press.
42. Michaelis M, Rothweiler F, Klassert D, von Deimling A, Weber K, et al. (2009) Reversal of P-glycoprotein-mediated multi-drug resistance by the MDM2 antagonist nudin-3. Cancer Res 69: 416-421.
43. Crosio C, Fimia GM, Loury R, Kimura M, Okano Y, et al. (2002) Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol 22: 874-885.
44. Kaestner P, Stolz A, Bastians H (2009) Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol Cancer Ther 8: 2046-2056.
45. Carr-Wilkinson J, O'Toole K, Wood KM, Challen CC, Baker AG, et al. (2010) High Frequency of p53/MDM2/p!4ARF Pathway Abnormalities in Relapsed Neuroblastoma. Clin Cancer Res 16: 1108-1118.
46. Chen L, Tweddle DA (2012) p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance. Front Oncol 2: 173.
47. Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, et al. (2005) Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A 102: 11011-11016.
48. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, et al. (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408: 297-315.